Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

Related Keywords

Denmark ,Spain ,Copenhagen ,Køavn ,Madrid ,Mansoor Raza Mirza ,European Society Of Medical Oncology ,European Society ,Medical Oncology ,Dostarlimab ,Endometrial Cancer ,Esmo Congress ,Ruby Trial ,